Submit your email to push it up the queue
ICON Clinical Research Limited, headquartered in Ireland (IE), is a leading global provider of outsourced development and commercialisation services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990, ICON has established itself as a trusted partner in clinical research, with a strong presence across Europe, North America, and Asia-Pacific. The company offers a comprehensive range of services, including clinical trial management, data management, and regulatory affairs, distinguished by its commitment to innovation and quality. ICON's unique approach integrates advanced technology and deep therapeutic expertise, enabling clients to navigate the complexities of clinical development efficiently. Recognised for its market leadership, ICON has achieved numerous accolades, reflecting its dedication to excellence and client satisfaction. With a robust portfolio and a focus on delivering results, ICON Clinical Research Limited continues to shape the future of clinical trials globally.
How does ICON Clinical Research Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
ICON Clinical Research Limited's score of 92 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
ICON Clinical Research Limited, headquartered in Ireland (IE), currently does not report specific carbon emissions data for the most recent year. As a current subsidiary of ICON Public Limited Company, any emissions data or climate commitments would be inherited from this parent organization. ICON Public Limited Company has established various climate initiatives, including commitments to the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for ICON Clinical Research Limited are not detailed in the available information. As part of its corporate family, ICON Clinical Research Limited aligns with broader industry standards and practices aimed at reducing carbon footprints and enhancing sustainability. The absence of specific emissions data highlights the need for ongoing transparency and commitment to climate action within the organisation.
Access structured emissions data, company-specific emission factors, and source documents
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|
Scope 1 | 1,827,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 18,796,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 3 | 36,726,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ICON Clinical Research Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.